TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* an age above 18 years~* consultation within 48 hours following a risk of HIV transmission (blood or sexual contact)~* indication for HIV post-exposure prophylaxis (according to French guidelines)~* person able to understand the nature of the study~* person who signed his consent form to participate in the study~Exclusion Criteria:~* person exposed to HIV risk from person infected by HIV, whose therapeutic history justifies the prescription of another combination of antiretroviral drugs~* contraindications to the prescription of Genvoy~* other medical contraindications~* person infected by hepatitis B virus~* pregnant or lactating woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genvoya (Type: EXPERIMENTAL): Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Is at least 18 years old at the screening visit (Visit 1).~* Has a diagnosis of FECD at Visit 1.~* Meet all other inclusion criteria outlined in clinical study protocol.~Exclusion Criteria:~* Has a study eye with a history of cataract surgery within 90 days of Visit 1.~* Has a study eye with a history of any previous ocular surgery other than for cataract.~* Meet any other exclusion criteria outlined in clinical study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- K-321 QID (Type: EXPERIMENTAL): K-321 Ophthalmic Solution Dose A
- K-321 BID (Type: EXPERIMENTAL): K-321 Ophthalmic Solution Dose B
- Placebo (Type: PLACEBO_COMPARATOR): Vehicle Solution Dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* BMI within 18.0 to 33.0 kg/m2, inclusive (minimum weight of 50.0 kg at Screening)~* Healthy, as determined by no clinically significant medical history, physical examination findings, 12-lead ECG findings, vital signs measurements, and laboratory results at screening, as judged by the investigator~* Current opioid users who had used oral opioids for recreational (non-therapeutic) purposes, at least 10 times in the past year~Exclusion Criteria:~* Drug or alcohol dependence within the last 12 months (except nicotine)~* Subjects who had ever been in treatment for substance use disorders (except smoking cessation~* History of presence of any clinically significant cardiac, neurologic, pulmonary, psychiatric, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, dermatologic, renal, or other major disease at screening, which in the opinion of the investigator, would have jeopardized the safety of the subject or the validity of the study results~* History or presence of hypotension, judged to be clinically significant based on investigator judgement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A:CL-108 22.5mg/975mg/37.5mg (Type: EXPERIMENTAL): CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth
- Treatment B:CL-108 37.5mg/1625mg/62.5mg (Type: EXPERIMENTAL): CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth
- Treatment C:M366 22.5mg/975mg (Type: ACTIVE_COMPARATOR): M366 22.5 mg/975 mg tablet by mouth
- Treatment D: M366 37.5mg/1625mg (Type: ACTIVE_COMPARATOR): M366 37.5 mg/1625 mg tablet by mouth
- Treatment E: Placebo (Type: PLACEBO_COMPARATOR): Placebo 0 mg tablet by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* relapsed or refractory CLL/SLL~* at least 18 years of age~* able to receive outpatient treatment and follow-up at the treating institution~* completed all CLL therapies \> 4 weeks prior to first study dose~Exclusion Criteria:~* previously treated with an anti-CD19 antibody therapy~* undergone prior allogeneic stem cell transplantation within 6 months or having active graft versus host disease~* active Richter's syndrome~* designated Class III or IV by the New York Heart Association (NYHA) criteria~* history of myocardial infarction or stroke within the last 6 months~* active viral, bacterial, or systemic fungal infection requiring treatment~* HIV or Hepatitis C positive~* Hepatitis B infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): XmAb5574

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Critically ill patients~2. Requirement for mechanical ventilation~3. At least one major risk factor for stress ulcer related bleeding~Exclusion Criteria:~1. History of gastric or oesophageal surgery~2. Evidence of active GI bleeding~3. Advanced renal disease~4. Treatment with any Proton Pump Inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Esomeprazole active treatment (Type: EXPERIMENTAL): iv esomeprazole 30 min intermittent infusions given for maximum 14 days
- Cimetidine active treatment (Type: ACTIVE_COMPARATOR): iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* 18-85 years old~* ASA Physical Status 1-3~* Scheduled for elective open or laparoscopic abdominal surgery, including colorectal and hysterectomy surgeries~* Anticipated hospitalization of three nights~* Expected requirement for parenteral opioids for at least 72 hours for postoperative pain~* Able to use IV PCA systems.~Exclusion Criteria:~* Hepatic disease, e.g. twice the normal levels of liver enzymes~* Kidney disease, e.g. twice the normal level of serum creatinine~* Bupivacaine sensitivity or known allergy~* Women who are pregnant or breastfeeding~* Anticoagulants considered to be a contraindication for epidural or TAP blocks.~* Surgeries with high port sites will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- TAP block with Exparel (Type: EXPERIMENTAL): Bilateral Transversus Abdominis Plane (TAP) block procedure following injection of liposomal bupivacaine (Exparel)
- Epidural analgesia with Bupivacaine (Type: ACTIVE_COMPARATOR): Epidural catheters with an infusion of Bupivacaine standard solution without additives

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial Evaluating Sildenafil Citrate in Relieving Ureteral Stent Related Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient aged \>18 years~Exclusion Criteria:~1. Patients who had LUTS before DJ stent fixation~2. DJ stent fixation after open surgery~3. Contraindication to Sildenafil citrate

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sildenafil (Type: ACTIVE_COMPARATOR): Patient in this arm will receive sildenafil citrate 50 mg tablet once daily after ureteral stent fixation.
- Placebo (Type: PLACEBO_COMPARATOR): Patient in this arm will receive placebo daily after ureteral stent fixation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Robotic Arm Rehabilitation in Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a clinically, defined, unilateral, hemiparetic stroke with radiologic exclusion of other diagnoses~* Stroke onset greater than six months before randomization for ischemic stroke patients and one year before randomization for hemorrhagic stroke patients~* A grade 3 or lower in Manual Muscle Test in the hemiparetic elbow flexion and shoulder abduction~Exclusion Criteria:~* Subjects unable to give informed consent~* Serious complicating medical illness~* Contracture or orthopedic problems limiting the range of joint movement in the study arm~* Visual loss~* Stroke occurred within 6 months for ischemic stroke patients, one year for hemorrhagic patients~* Botox treatment within 3 months of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Robot Exercise Group
- Arm 2 (Type: ACTIVE_COMPARATOR): Traditional Upper Extremity Exercise Group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Cognitive Dysfunction as Geriatric Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age 65 or older~* absence of sensory impairment (deafness)~* full legal capacity~* informed consent~* ability to speak~* elective or acute surgical procedure~Exclusion Criteria:~* somnolence, coma~* sepsis~* Glasgow coma scale 14 and less~* known psychiatric disease~* effect of premedication, drugs

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: None): Patients above 65 years old undergoing surgery in general or regional anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged ≥ 19 years~2. Histopathologically diagnosed AK patients with at least 1 macroscopic and discrete lesion within a contiguous 25 cm2 (e.g. 5 cm x 5 cm) of treatment area~3. The treatment area including the lesion must be accessible to apply the investigational product. However, the lesions on lips, mucosa, outer ear (concha) and those around eyes are excluded.~4. Subjects who signed the written informed consent prior to perform any study-related procedures or assessments, including photographs of their treatment area for documentation and efficacy assessment.~Exclusion Criteria:~1. Hypersensitivity to any components of the investigational product~2. History or evidence of skin conditions that could interfere with evaluation of the investigational product(e.g., eczema, unstable psoriasis, xeroderma pigmentosa, inflammatory or infectious disease around the selected treatment area)~3. Unhealed wound within 5 cm, or basal cell carcinoma or squamous cell carcinoma within 10 cm from the selected treatment area.~4. Subjects who received or expected to receive any of the following pharmacotherapy and non-pharmacotherapy or procedures during the treatment and follow-up period~5. Subjects who have following disorder or abnormal laboratory result~6. Pregnant, lactating, and childbearing potential women who are unwilling to practice effective contraception; for example, oral contraceptives, hormonal methods, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods (i.e., condom or occlusive cap with spermicidal foam/gel/film/cream/suppository), male sterilization, and abstinence.~7. Subjects who previously underwent another clinical trial within 30 days or 5-times the half-life of previous investigational product prior to baseline (the longer period of time must be considered).~8. Other conditions by investigator's discretion to be inappropriate for this clinical study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ingenol mebutate gel 0.015% (Type: ACTIVE_COMPARATOR): Applied on face and scalp for three days.
- ingenol mebutate gel 0.05% (Type: ACTIVE_COMPARATOR): Applied on trunk and extremities for two days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate D-1553 in Subjects With Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with histologically proven, locally advanced, unresectable and/or metastatic NSCLC for which no standard treatment is available or the subject is refractory to or intolerant of existing standard treatment.~* Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA. Historical, local laboratory result (up to 5 years prior to this study) can be used for Phase 1 subjects. Phase 2 subjects must be tested for KRasG12C mutation by a central laboratory.~* Subject has measurable disease according to RECIST, v1.1~Exclusion Criteria:~* Subject with unstable or progressive central nervous system (CNS) metastases.~* Subjects with clinically significant cardiovascular disease~* Subject with interstitial lung disease (ILD) or any active systemic infection including but not limited to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.~* Subject has impaired gastrointestinal (GI) function or GI diseases that may significantly alter the absorption or metabolism of oral medications.~* Subject is pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1a Dose escalation of D-1553 (Type: EXPERIMENTAL): Phase 1a will evaluate up to sequential cohorts with different doses of D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation
- Phase 1b Dose expansion of D-1553 (Type: EXPERIMENTAL): Phase 1b will evaluate more subjects with up to 2 different doses of D-1553 to confirm the recommended phase 2 dose.
- Phase 2 of D-1553 monotherapy (Type: EXPERIMENTAL): Phase 1b will evaluate more subjects at the recommended phase 2 dose of D-1553 to evaluate the efficacy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A New Surgical-restorative Approach to Treat Gingival Recessions Associated With Non-carious Cervical Lesions (NCCL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* presenting Miller class I or II gingival recession in the maxillary canines or premolars associated with non-carious cervical lesion;~* teeth included in the study should present pulp vitality;~* patients presenting no signs of active periodontal disease and full-mouth plaque and bleeding score ≤ 20%;~* patients older than 18 years old;~* probing depth ˂ 3 mm in the included teeth;~* patients who agreed to participate and signed an informed consent form~Exclusion Criteria:~* patients with systemic problems (cardiovascular, blood dyscrasias, immunodeficiency, and diabetes, among others) that will contraindicate the surgical procedure~* patients taking medications known to interfere with the wound healing process or that contraindicate the surgical procedure~* smokers or pregnant women~* patients who underwent periodontal surgery in the area of interest.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Connective tissue graft (CTG) (Type: ACTIVE_COMPARATOR): After local anesthesia, the surgical procedure performed was the trapezoidal-type of Coronally advanced flap (CAF). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
- CTG plus resin composite restoration (Type: EXPERIMENTAL): After local anesthesia, a sterile rubber dam was placed to isolate the operative field and the coronal zone of the non-carious cervical lesion restoration was performed with a nanocomposite resin, following the manufacturer's instructions. The apical margin of the restoration was place 1 millimeter beyond to the cemento-enamel junction estimation. In the next session, the surgical procedure performed was the trapezoidal-type of CAF. After the trapezoidal-type of CAF flap was raised, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of diabetes mellitus~* intractable diffuse DME (diffuse DME which did not respond to or recurred after the previous IVTA and/or macular focal laser photocoagulation)~* the central macular thickness (CMT) greater than 250 μm~Exclusion Criteria:~* presence of vitreomacular traction~* a prior history of treatment for the DME within 3 months or vitreoretinal surgery

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Migraine headache (International Classification of Headache Disorders 3B criteria)~Exclusion Criteria:~* Brain imaging ordered~* Fever~* Objective neurological findings~* Pregnancy/ breast feeding~* Allergy/ contraindication to investigational medication~* History of addiction to opioids, use of methadone, any use of opioids previous 30 days

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydromorphone (Type: ACTIVE_COMPARATOR): Hydromorphone 1mg, administered as intravenous drip over 5 minutes. Patients can receive second 1mg dose at 1 hour.
- Prochlorperazine (Type: ACTIVE_COMPARATOR): Prochlorperazine 10mg, administered as intravenous drip over 5 minutes. Diphenhydramine 25mg co-administered.~Patients can receive second 10mg dose at 1 hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete